EOLS | Evolus, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	16.54 - 17.70
52 Week Range	7.44 - 17.70
Beta	1.36
Implied Volatility	41.38%
IV Rank	28.04%
Day's Volume	739,767
Average Volume	537,795
Shares Outstanding	63,094,500
Market Cap	1,058,094,765
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	2018-02-08

Valuation
Profitability
Growth
Health
P/E Ratio	-18.63
Forward P/E Ratio	N/A
EPS	-0.90
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	304
Country	USA
Website	EOLS

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

EOLS's peers: ALKS, AMPH, AMRX, ASRT, VNRX, COLL, EGRX, PAHC, ANIP, PROC, SSIC, DCPH, PBH, PCRX, ITCI, AAWH, IXHL, SUPN, OPTN

*Chart delayed

Analyzing fundamentals for EOLS we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is poor, Growth is bad and Health is very weak. For more detailed analysis please see EOLS Fundamentals page.

Watching at EOLS technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on EOLS Technicals page.